Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Companion animal trials to help human patients
Professor Wouda
The study focuses on dogs because of the similarities between their cancers and human cancers.

Researchers test innovative treatment options 

Clinical trials to treat cancers in cats, dogs, and other companion animals are underway at Kansas State University.

Raelene Wouda, assistant professor of clinical sciences, is offering groundbreaking new treatments to pet owners at a reduced cost.

In addition to improved diagnostic testing and monitoring approaches, the trials include innovative treatment options including combination chemotherapy, t-cell transfer and nanoparticle drug formulations.


As well as improving outcomes for veterinary patients, Wouda hopes the research will provide important information for how the disease can be better diagnosed, monitored and treated in humans.


“For many pet owners, cancer is a terminal diagnosis for they beloved family member,” Wouda said. “These studies provide an opportunity to trial a cutting-edge therapy for their pets at a reasonable price.”

“Moreover, owners participating in these clinical trials take comfort and are pleased to know that they are helping to achieve better treatments and outcomes for pets that may be diagnosed with cancer in the future.”

Professor Wouda’s research, published in the journal Veterinary Comparative Oncology, has been described as a ‘crucial step’ towards a long-term cure for many cancers.

The study focuses on dogs because of the similarities between their cancers and human cancers, like melanoma, lung cancer and osteosarcoma.


Dogs also live with us and are exposed to the same environmental factors, explained Wouda. Furthermore, because dogs age faster than humans, their disease progresses faster, which is a practical advantage for evaluating the efficacy and clinical benefits of new treatments.

"We get clinical answers more quickly in dogs," Wouda said. "The benefit of a particular therapy becomes evident in dogs more rapidly compared to people, and because of this we can preserve research and development finances, but more importantly, we save valuable time and resources."

Professor Wouda will work with graduate students, oncology technicians and referral veterinary surgeons to conduct the clinical trials.

She will also collaborate with human medical researchers to discuss how the research can be best applied to the field of human oncology.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.